Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up
Andrew J. Portuguese,
Jennifer J. Huang,
Yein Jeon,
Mahnoosh Taheri,
Aya Albittar,
Emily C. Liang,
Alexandre V. Hirayama,
Erik L. Kimble,
Lorenzo Iovino,
Christina Poh,
Ajay K. Gopal,
Mazyar Shadman,
Brian G. Till,
Filippo Milano,
Aude G. Chapuis,
Folashade Otegbeye,
Ryan D. Cassaday,
Ryan S. Basom,
Qian Vicky Wu,
David G. Maloney,
Jordan Gauthier
Affiliations
Andrew J. Portuguese
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA
Jennifer J. Huang
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA
Yein Jeon
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA
Mahnoosh Taheri
Washington State University, Pullman, WA
Aya Albittar
University of Washington, Seattle, WA, USA; MD Anderson Cancer Center, Houston, TX
Emily C. Liang
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA
Alexandre V. Hirayama
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA
Erik L. Kimble
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA
Lorenzo Iovino
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA
Christina Poh
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA
Ajay K. Gopal
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA
Mazyar Shadman
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA
Brian G. Till
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA
Filippo Milano
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA
Aude G. Chapuis
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA
Folashade Otegbeye
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA
Ryan D. Cassaday
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA
Ryan S. Basom
Fred Hutchinson Cancer Center, Seattle, WA
Qian Vicky Wu
Fred Hutchinson Cancer Center, Seattle, WA
David G. Maloney
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA
Jordan Gauthier
Fred Hutchinson Cancer Center, Seattle, WA, USA; University of Washington, Seattle, WA
Lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) are FDA- and EMAapproved chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory large B-cell lymphoma (LBCL). However, comparative real-world analyses of their efficacy and toxicity with extended follow-up are lacking. We conducted a retrospective study of 160 LBCL patients treated at the Fred Hutchinson Cancer Center with commercial liso-cel or axi-cel per standard of care. Using inverse probability of treatment weighting (IPTW) to mitigate treatment allocation bias and multivariable adjustments to minimize other sources of confounding, we assessed the impact of CAR T-cell product type on outcomes. Axi-cel was associated with significantly higher rates of cytokine release syndrome (CRS; G1+: adjusted OR [aOR] 4.27, p=0.004; G2+: aOR 2.88, p=0.006), immune effector cell-associated neurotoxicity syndrome (ICANS; G1+: aOR 2.10, p=0.048), and immune effector cell-associated hematotoxicity (ICAHT; G1+: aOR 8.09, p
